肾移植同种免疫风险分层
该综述讨论了肾移植中同种免疫风险分层的两个支柱:HLA相容性(HLA-DSA缺失)和HLA匹配程度。文章重点介绍了HLA分子错配算法在提高风险分层精确性方面的进展、临床证据、局限性和临床可实施性,并概述了不同分子错配工具及其在个体化医疗中的潜在应用。
要点
- HLA相容性(HLA-DSA缺失)和HLA匹配程度是同种免疫风险评估的两大支柱。
- 基于抗原水平HLA数据的风险分层对个体患者长期移植物结局预测能力有限。
- HLA分子错配算法有望提高风险分层精确性并应用于个体化医疗。
核心结论
- HLA分子错配分析可提高肾移植同种免疫风险分层的精确性,但需认识其局限性和临床可实施性。
研究设计与样本
- 综述,讨论HLA分子错配分析的进展、临床证据、局限性和临床可实施性,并概述不同分子错配工具及其潜在应用。
主要发现
- 单抗原微珠检测提高了抗HLA抗体检测的敏感性和特异性,HLA分型从血清学进步到DNA水平有助于更详细分析HLA相容性。
- 基于抗原水平HLA数据的同种免疫风险分层在个体患者层面对预测移植后新发抗HLA应答和长期移植物结局的能力有限。
临床怎么用
- HLA分子错配工具潜在应用于器官分配、供者接受标准和个体化免疫抑制。
局限性
- 基于抗原水平HLA数据的风险分层预测新发抗HLA应答和长期移植物结局的能力有限,尤其是个体患者层面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alloreactivity after kidney transplantation occurs via both memory responses resulting from prior sensitization and de novo responses that develop due to donor-recipient disparity for the human leukocyte antigen (HLA) complex. HLA compatibility (absence of HLA-DSA) and the degree of HLA matching inform on the likelihood of allorecognition that can cause allograft rejection and allograft loss, and are therefore the two pillars of alloimmune risk assessment. Over the past decades, the detection of anti-HLA antibodies has become more sensitive and specific through single antigen bead testing, and advances in HLA typing from serology to DNA level have been instrumental for more detailed analysis of HLA compatibility. Nonetheless, alloimmune risk stratification using antigen-level HLA data has limited ability to accurately predict the risk of de novo anti-HLA responses and long-term graft outcome after transplantation, especially on the individual patient level. Aiming to improve long-term outcomes by improving HLA matching, HLA molecular mismatch algorithms have been developed. In this review, we discuss the advances, clinical evidence, limitations and clinical implementability of HLA molecular mismatch analysis to increase precision in alloimmune risk stratification in kidney transplantation. In addition, we provide an overview of the different molecular mismatch tools and their potential application in personalized medicine, such as organ allocation, criteria for donor acceptance and individualized immunosuppression.
引用
- Bezstarosti, Senev, Morris, et al. Alloimmune risk stratification for kidney transplantation. Kidney Int. 2026. PMID: 42957129. doi:10.1016/j.kint.2026.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。